Evidence map›Paper›PMID 30568903›Full record

ArticleAfrican journal of laboratory medicine2018

Multi-drug resistant

Kome Otokunefor, Tosanwumi V Otokunefor, Godwin Omakwele

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African journal of laboratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Rifampicin-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kome OtokuneforDepartment of Microbiology, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.ORCID https://orcid.org/0000-0002-9860-1749
Tosanwumi V OtokuneforDepartment of Microbiology, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.ORCID https://orcid.org/0000-0001-7605-8450
Godwin OmakweleDepartment of Microbiology, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.ORCID https://orcid.org/0000-0002-8246-3601
University of Port Harcourt · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn past years, much focus has been on tackling the scourge and spread of tuberculosis worldwide. The recent emergence of multi-drug resistant (MDR) tuberculosis has, however, negatively threatened progress made so far. Nigeria ranks fourth out of the 22 high tuberculosis burden countries in the world and has the highest burden of tuberculosis in Africa. It is therefore necessary to monitor the MDR tuberculosis situation in the country.

objectivesThis study set out to assess the proportions of MDR tuberculosis in patients attending six directly observed treatment short-course centres in Port Harcourt, Nigeria, from October 2015 to October 2016.

methodsSix hundred and nine participants between the ages of 18 and 75 years were enrolled in this study and comprised suspected and newly diagnosed tuberculosis cases. Sputum samples obtained from the participants were screened for the presence of

resultsOf the 609 participants enrolled, 30 (4.9%) were confirmed as

conclusionThis study reports a low rate of MDR tuberculosis and contributes to the sparse data on drug resistant tuberculosis in Nigeria.

Identifiers

PMID30568903
PMCPMC6295751
OpenAlexW2904550296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.